{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:17:55Z","timestamp":1784557075638,"version":"3.55.0"},"reference-count":16,"publisher":"Bioscientifica","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["edm.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>In patients with diabetes mellitus, the toxic milieu caused by abnormal glucose and free fatty acid handling can lead to heart failure (HF). Referred to as diabetic cardiomyopathy (DMCM), this syndrome often exists in the absence of conventional risk factors for HF such as history of myocardial infarction or hypertension. Low-carbohydrate diets (LCDs) have recently been endorsed as an efficacious therapeutic dietary approach to prevent and reverse cardiometabolic disease including type 2 diabetes mellitus (T2DM). LCDs improve systemic insulin resistance (IR), reverses cardiac remodelling in a rodent model and downregulates the expression of sodium\u2013glucose co-transporter 2 (SGLT2) receptors in the kidney. It is therefore conceivable that a lifestyle approach such as adopting an LCD can be offered to patients with DMCM. The reported case is that of a 45-year-old man with a 15-year history of non-ischaemic cardiomyopathy, T2DM and obesity. The patient volunteered to engage in a 16-week low-carbohydrate dietary intervention trial and then self-selected to remain on this diet for 1 year. The whole-food LCD was based on simple \u2018traffic light\u2019 style food lists and not designed to restrict calories, protein, fat or salt. After 1 year, the patient had lost 39 kg and his cardiometabolic markers had significantly improved. LCDs present a potentially beneficial approach for patients with DMCM and could be considered as a lifestyle intervention before SGLT2i therapy is commenced.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Learning points<\/jats:title>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>Diabetic cardiomyopathy (DMCM) is a syndrome precipitated mainly by the detrimental effects of glucose metabolism disorders such as insulin resistance and diabetes.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Low-carbohydrate diets (LCD) mimic many effects of sodium\u2013glucose co-transporter 2 inhibitors (SGLT2i).<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>LCDs are a dietary pattern which can have significant and beneficial effects on metabolic and anthropometric markers in patients with DMCM.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>LCDs and SGLT2i therapy could be combined and may achieve better clinical outcomes for patients with DMCM.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Combination therapy may be carried out under close supervision as the real risk for diabetic ketoacidosis remains.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:sec>","DOI":"10.1530\/edm-23-0086","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T07:04:56Z","timestamp":1702451096000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":0,"title":["A low-carbohydrate diet in place of SGLT2i therapy in a patient with diabetic cardiomyopathy"],"prefix":"10.1530","volume":"2023","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7506-1332","authenticated-orcid":true,"given":"Sabine","family":"Kleissl-Muir","sequence":"first","affiliation":[{"name":"Deakin University School of Nursing and Midwifery, Geelong, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodil","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Deakin University School of Nursing and Midwifery, Geelong, Victoria, Australia"},{"name":"School of Nursing and Midwifery, Centre for Quality and Patient Safety, Institute for Health Transformation, Deakin University, Geelong, Victoria, Australia"},{"name":"The Centre for Quality and Patient Safety, Institute of Health Transformation -Western Health Partnership, Western Health, St Albans, Victoria, Australia"},{"name":"Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"Faculty of Health Sciences, University of Southern Denmark and Steno Diabetes Centre, Odense M, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Owen","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caryn","family":"Zinn","sequence":"additional","affiliation":[{"name":"Human Potential Centre, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Driscoll","sequence":"additional","affiliation":[{"name":"Deakin University School of Nursing and Midwifery, Geelong, Victoria, Australia"},{"name":"School of Nursing and Midwifery, Centre for Quality and Patient Safety, Institute for Health Transformation, Deakin University, Geelong, Victoria, Australia"},{"name":"School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Cardiology, Austin Health, Heidelberg, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Heart Failure Reviews","first-page":"279","article-title":"Diabetic cardiomyopathy: molecular mechanisms, detrimental effects of conventional treatment, and beneficial effects of natural therapy","volume":"24","author":"Parim","year":"2019","unstructured":"Parim BSathibabu Uddandrao VV & Saravanan G. Diabetic cardiomyopathy: molecular mechanisms, detrimental effects of conventional treatment, and beneficial effects of natural therapy. Heart Failure Reviews201924279\u2013299. (https:\/\/doi.org\/10.1007\/s10741-018-9749-1)"},{"key":"bib2","series-title":"Journal of the American Heart Association","first-page":"e026184","article-title":"Insulin resistance is associated with heart failure with recovered ejection fraction in patients without diabetes","volume":"11","author":"Yang","year":"2022","unstructured":"Yang CDPan WQFeng SQuan JWChen JWShu XYAihemaiti MDing FHShen WFLu L, Insulin resistance is associated with heart failure with recovered ejection fraction in patients without diabetes. Journal of the American Heart Association202211e026184. (https:\/\/doi.org\/10.1161\/JAHA.122.026184)"},{"key":"bib3","series-title":"International Journal of Molecular Sciences","first-page":"3587","article-title":"Pathophysiology and treatment of diabetic cardiomyopathy and heart failure in patients with diabetes mellitus","volume":"23","author":"Nakamura","year":"2022","unstructured":"Nakamura KMiyoshi TYoshida MAkagi SSaito YEjiri KMatsuo NIchikawa KIwasaki KNaito T, Pathophysiology and treatment of diabetic cardiomyopathy and heart failure in patients with diabetes mellitus. International Journal of Molecular Sciences2022233587. (https:\/\/doi.org\/10.3390\/ijms23073587)"},{"key":"bib4","series-title":"Heart Failure Clinics","first-page":"341","article-title":"Diabetic cardiomyopathy: definition, diagnosis, and therapeutic implications","volume":"15","author":"Paolillo","year":"2019","unstructured":"Paolillo SMarsico FPrastaro MRenga FEsposito LDe Martino FDi Napoli PEsposito IAmbrosio AIanniruberto M, Diabetic cardiomyopathy: definition, diagnosis, and therapeutic implications. Heart Failure Clinics201915341\u2013347. (https:\/\/doi.org\/10.1016\/j.hfc.2019.02.003)"},{"key":"bib5","series-title":"Heart Failure Reviews","first-page":"961","article-title":"SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism","volume":"27","author":"Wang","year":"2022","unstructured":"Wang XNi JGuo RLi LSu JHe F & Fan G. SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism. Heart Failure Reviews202227961\u2013980. (https:\/\/doi.org\/10.1007\/s10741-021-10096-8)"},{"key":"bib6","series-title":"Federal Practitioner","first-page":"45","article-title":"Risks vs benefits for SGLT2 inhibitor medications","volume":"35","author":"Pittampalli","year":"2018","unstructured":"Pittampalli SUpadyayula SMekala HM & Lippmann S. Risks vs benefits for SGLT2 inhibitor medications. Federal Practitioner20183545\u201348."},{"key":"bib7","series-title":"Journal of Human Hypertension","first-page":"649","article-title":"The \u201cdiscordant doppelganger dilemma\u201d: SGLT2i mimics therapeutic carbohydrate restriction - food choice first over pharma?","volume":"35","author":"Murray","year":"2021","unstructured":"Murray SWMckelvey SHeseltine TDHenderson GSingh JUnwin D & Brady AJB. The \u201cdiscordant doppelganger dilemma\u201d: SGLT2i mimics therapeutic carbohydrate restriction - food choice first over pharma?Journal of Human Hypertension202135649\u2013656. (https:\/\/doi.org\/10.1038\/s41371-021-00482-y)"},{"key":"bib8","series-title":"Journal of Clinical Investigation","first-page":"1083","article-title":"The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man","volume":"12","author":"Chasis","year":"1933","unstructured":"Chasis HJolliffe N & Smith HW. The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man. Journal of Clinical Investigation1933121083\u20131090. (https:\/\/doi.org\/10.1172\/JCI100559)"},{"key":"bib9","series-title":"Frontiers in Nutrition","first-page":"688540","article-title":"Adapting medication for type 2 diabetes to a low carbohydrate diet","volume":"8","author":"Cucuzzella","year":"2021","unstructured":"Cucuzzella MRiley K & Isaacs D. Adapting medication for type 2 diabetes to a low carbohydrate diet. Frontiers in Nutrition20218688540. (https:\/\/doi.org\/10.3389\/fnut.2021.688540)"},{"key":"bib10","series-title":"Journal of Insulin Resistance","first-page":"1","article-title":"Low carbohydrate diet for diabetic cardiomyopathy: protocol for a randomised controlled trial","volume":"5","author":"Kleissl-Muir","year":"2022","unstructured":"Kleissl-Muir SZinn CRasmussen BOwen A & Driscoll A. Low carbohydrate diet for diabetic cardiomyopathy: protocol for a randomised controlled trial. Journal of Insulin Resistance202251\u20138. (https:\/\/doi.org\/10.4102\/jir.v5i1.73)"},{"key":"bib12","series-title":"LowCarb USA","first-page":"1","article-title":"Schpritzler F, Westman EC & Yancy WS Jr. Clinical guidelines for therapeutic carbohydrate restriction","author":"Hite","year":"2019","unstructured":"Hite AHCavan DCywes REde GFettke GLenzkes BNoakes TD & Scher B. Schpritzler F, Westman EC & Yancy WS Jr. Clinical guidelines for therapeutic carbohydrate restriction. LowCarb USA, pp. 1\u2013202019. Available at: https:\/\/www.lowcarbusa.org\/clinical-guidelines\/"},{"key":"bib13","series-title":"Circulation","first-page":"1383","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","unstructured":"Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis. Circulation20221461383\u20131405. (https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061732)"},{"key":"bib14","series-title":"AACE Clinical Case Reports","first-page":"17","article-title":"Euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors and a ketogenic diet: a case series and review of literature","volume":"7","author":"Mistry","year":"2021","unstructured":"Mistry S & Eschler DC. Euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors and a ketogenic diet: a case series and review of literature. AACE Clinical Case Reports2021717\u201319. (https:\/\/doi.org\/10.1016\/j.aace.2020.11.009)"},{"key":"bib15","series-title":"BMJ Open Diabetes Research and Care","first-page":"1","article-title":"Differential effects of sodium-glucose cotransporter 2 inhibitor and low-carbohydrate diet on body composition and metabolic profile in obese diabetic db\/db mice","volume":"8","author":"Kusakabe","year":"2020","unstructured":"Kusakabe TYokota SShimizu MInoue TTanaka MOhue-Kitano RMuranaka KYamakage HWada HHasegawa K, Differential effects of sodium-glucose cotransporter 2 inhibitor and low-carbohydrate diet on body composition and metabolic profile in obese diabetic db\/db mice. BMJ Open Diabetes Research and Care202081\u201311. (https:\/\/doi.org\/10.1136\/bmjdrc-2020-001303)"},{"key":"bib16","series-title":"Endocrinology, Diabetes and Metabolism Case Reports","first-page":"e381","article-title":"The DAPA-DIET study: metabolic response to Dapagliflozin combined with dietary carbohydrate restriction in patients with type 2 diabetes mellitus and Obesity\u2014A longitudinal cohort study","volume":"5","author":"Hanson","year":"2022","unstructured":"Hanson PRandeva HCuthbertson DJO\u2019Hare PJParsons NChatha KReidy GWeickert MO & Barber TM. The DAPA-DIET study: metabolic response to Dapagliflozin combined with dietary carbohydrate restriction in patients with type 2 diabetes mellitus and Obesity\u2014A longitudinal cohort study. Endocrinology, Diabetes and Metabolism Case Reports20225e381. (https:\/\/doi.org\/10.1002\/edm2.381)"},{"key":"bib17","series-title":"Health Psychology","first-page":"166","article-title":"Self-efficacy as a marker of cardiac function and predictor of heart failure hospitalization and mortality in patients with stable coronary heart disease: findings from the heart and soul study","volume":"28","author":"Sarkar","year":"2009","unstructured":"Sarkar UAli S & Whooley MA. Self-efficacy as a marker of cardiac function and predictor of heart failure hospitalization and mortality in patients with stable coronary heart disease: findings from the heart and soul study. Health Psychology200928166\u2013173. (https:\/\/doi.org\/10.1037\/a0013146)"}],"container-title":["Endocrinology, Diabetes &amp; Metabolism Case Reports"],"original-title":[],"link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2023\/4\/EDM23-0086.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2023\/4\/EDM23-0086.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2023\/4\/EDM23-0086.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:48:17Z","timestamp":1784555297000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/edm\/article\/3615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":16,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1530\/edm-23-0086","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,1]]}}}